Advanced Biological Laboratories and Right to Care collaborate to strengthen HIV treatment

Advanced Biological Laboratories S.A. and Right to Care enter into an exclusive distribution and development collaboration (open source) agreement covering EQUIP in 17 developing countries to strengthen HIV (and other infectious disease) treatment and prevention.

Johannesburg (South Africa), Boston (USA), Luxembourg (Luxembourg Grand Duchy), Tuesday, 4 July 2017: Advanced Biological Laboratories (ABL) S.A. and Right to Care today announced that they entered into a license agreement for the distribution of ABL products. The agreement is open source access to ABL’s products for Right to Care and exclusive distribution rights in 17 countries covered by EQUIP, a USAID funded programme, led by Right to Care. The intention is to collaborate in the development, testing and scaling of innovative approaches that increase HIV testing, care and treatment. The implementation vehicle for this collaboration is a joint venture between the Right to Care Group and the Foundation for Professional Development Group called Qode.

The agreement is effective immediately and covers a large panel of ABL software (as well as all the future enhancements on such system following interactions with infectious diseases experts) including electronic medical record systems (TherapyEdge® and Nadis®), viral hepatitis web register (HepatiC®), Woman Health related web register (WHP), an innovative consolidation and reporting platform specifically designed for medical and related data (Octoplus™), and Sanger/NGS reagents and the related data analysis platform (ViroScore® and DeepChek®) software which are already CE & IVD certified.

“This is the first time in ABL history where we have provided access to the source code of our products to improve and adapt them to local needs. Through our relationship with Right to Care, we aim to provide broadest access at local pricing to contribute to improved patient clinical outcomes. Our large product portfolio consists of clinical and laboratory software, drug resistance and genotyping products in the field of infectious diseases (HIV, TB, Viral Hepatitis and other infections diseases). With the experience of Right to Care, we will build personalized tools, enable current and future programs led by PEPFAR and NGOs, to address specific needs to help the local populations and authorities benefit from optimal patient management systems and products,” said Dr Chalom Sayada, CEO of ABL.

Prof Ian Sanne, CEO of Right to Care, comments, “We are grateful for ABL’s vision to support developing countries with crucial data analysis requirements. We trust this collaboration will be mutually beneficial.”


About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ ,the DPM and Nadis® (thanks to the acquisition of Fédialis Médica in 2016) which are used for data and patient management, monitoring and personalized reporting applications. In 2012, TherapyEdge (respectively ViroScore® and DeepChek®-HIV ) received CE-marking (respectively CE-marking for IVD use). ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL’s DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.

About Right to Care
Right to Care is a South African non-profit organisation that supports and delivers prevention, care, and treatment services for HIV and TB. Through technical assistance, Right to Care supports the private sector, the Department of Health and the Department of Correctional Services. In addition, through direct service delivery, Right to Care treats patients for HIV, TB, cervical cancer and sexually transmitted infections. It leads the EQUIP consortium in 17 developing countries.

EQUIP supports the United States Agency for International Development’s (USAID) commitment, through the US President’s Emergency Plan for AIDS Relief (PEPFAR), to end the HIV/Aids epidemic, by fast-tracking cost effective treatment and prevention initiatives in 17 countries. With novel approaches, EQUIP supports the rapid diagnosis, viral suppression and linkage to sustained treatment for people living with HIV, ultimately working towards the UNAIDS 90-90-90 targets.

About Qode
Qode is a joint venture between Right to Care and the Foundation for Professional Development to house thirteen software offerings which are used in the development, testing and scaling of innovative approaches that reduce HIV/Aids. Qode will provide its products in 17 countries, through EQUIP, an initiative which works towards the eradication of HIV/Aids.